Serivan 17

 

Investigated for use/treatment in neurologic disorders, parkinson's disease, psychosis, schizophrenia and schizoaffective disorders, and sleep disorders.

Anti-Parkinson Drugs

ACP-103 reduces haloperidol-induced akathisia, a debilitating extrapyramidal side effect (EPS), in patients with schizophrenia. ACP-103 is a 5-HT2A inverse agonist, to reduce the side effects associated with antipsychotic drug treatment with haloperidol. ACP-103 reduced both the motor disturbances and hyperprolactinemia, a condition of elevated prolactin secretion, caused by haloperidol treatment.

Recommended dose: 34 mg capsule taken orally once daily, without titration

• Coadministration with strong CYP3A4 inhibitors (e.g., ketoconazole) increases exposure. Reduce dose to 10 mg taken orally as one tablet once daily.
• Coadministration with strong or moderate CYP3A4 inducers reduces exposure. Avoid concomitant use of strong or moderate CYP3A4 inducers with it.

contraindicated in patients with a history of a hypersensitivity reaction to pimavanserin or any of its components. Rash, urticaria, and reactions consistent with angioedema (e.g., tongue swelling, circumoral edema, throat tightness, and dyspnea) have been reported.

Nausea, Constipation, Peripheral edema, Gait disturbance, Hallucination, Confusional state.

There are no data on Pimavanserin use in pregnant women that would allow assessment of the drug-associated risk of major congenital malformations or miscarriage. There is no information regarding the presence of pimavanserin in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Pimavanserin and any potential adverse effects on the breastfed infant from Pimavanserin or from the underlying maternal condition.

The pre-marketing clinical trials involving NUPLAZID in approximately 1200 subjects and patients do not provide information regarding symptoms with overdose. In healthy subject studies, dose-limiting nausea and vomiting were observed.

Store at 20°C to 25°C.

Safe

Pimavanserin 17mg